Evolent Health Inc
EVH
ISIN null / Valor 28153126
Evolent Health Inc
UMushroom community rating:
About company
Evolent Health Inc is a healthcare technology and services company that partners with health systems to help them transition to value-based care.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (06.10.2025):
Evolent Health Inc reported its financial results for the fourth quarter of 2024, demonstrating robust revenue growth and strategic advancements despite ongoing challenges in the healthcare sector.
Revenue Growth
For the three months ended December 31, 2024, Evolent Health Inc achieved revenue of $646.5 million, representing a 16.3% increase compared to the same period in 2023. For the full year ended December 31, 2024, total revenue reached $2.55 billion, marking a 30.1% growth over 2023.
Net Loss
The company reported a net loss attributable to common shareholders of $30.6 million for the fourth quarter of 2024 and $93.5 million for the full year, with net loss margins of 4.7% and 3.7%, respectively.
Adjusted EBITDA
Adjusted EBITDA stood at $22.6 million for the three months ended December 31, 2024, and $160.5 million for the year, resulting in Adjusted EBITDA margins of 3.5% and 6.3%, respectively.
Contract Amendments
Evolent Health Inc signed contract amendments in all three Performance Suite negotiations, anticipated to deliver an annual improvement of $115 million for 2025 compared to Q4 2024, surpassing the initial target of $100 million.
Customer Retention
The company maintained a 100% retention rate across its top customers, who collectively account for over 90% of its 2024 revenue.
New Revenue Agreements
Evolent Health Inc announced two new revenue agreements in the fourth quarter, further enhancing its growth trajectory for the upcoming year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
434 M
Market cap (USD)
6,456,195
Daily traded volume (Shares)
11.08 / 10.82
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Timo R
Antonio Granic
EQUITIES OF THE SAME SECTOR
